# PFAS and Cancer: IARC Groups, Kidney and Testicular Signals > PFOA is Group 1. PFOS is Group 2B. Hazard is not the same as your personal risk. *Published 2026-07-10 · Updated 2026-07-10 · By Elena Voss* In short IARC (2023): **PFOA Group 1** (carcinogenic to humans); **PFOS Group 2B** (possibly carcinogenic). Strongest human signals: **kidney and testicular cancers** in highly exposed C8/occupational cohorts. Hazard ≠ individual risk—dose, duration, and co-factors matter. Cancer is the endpoint that forces careful language. PFAS chemistry earned hard classifications; personal risk still depends on exposure intensity that NHANES averages cannot fully capture for hotspots. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What exactly did IARC classify? In November 2023, IARC placed PFOA in Group 1 and PFOS in Group 2B after Monographs evaluation that integrated human epidemiology, animal bioassays, and key characteristics of carcinogens. Not every PFAS molecule shares those two labels. Quote the groups precisely. Do not expand Group 1 language to the entire PFAS universe without compound-specific evaluation. ## Where do human cancer signals come from? The C8 Science Panel’s probable-link conclusions for kidney and testicular cancer are foundational community epidemiology after industrial PFOA contamination. Occupational cohorts and follow-up literature reinforce renal and testicular signals at high exposures. Six C8 probable-link disease categories also included ulcerative colitis, thyroid disease, hypercholesterolemia, and pregnancy-induced hypertension—broader than cancer alone. Key reference points ItemStatus PFOA IARCGroup 1 (2023) PFOS IARCGroup 2B (2023) Strongest human cancersKidney, testicular Key community studyC8 Science Panel High clinical tier≥20 ng/mL sum (NASEM) EPA PFOA/PFOS MCL4.0 ppt each (rule context) ## How should clinicians use serum tiers? ATSDR summaries of NASEM guidance escalate cancer-oriented symptom assessment as serum sum rises, with age-specific prompts. Blood testing is a exposure and care-planning tool, not a cancer screen by itself. General-population readers should not treat a detectable NHANES-range level as a diagnosis. Hotspot communities and workers need tailored public-health and clinical pathways. ## What actions reduce population cancer risk from PFAS? Lower long-term intake via drinking-water compliance and point-of-use treatment where appropriate, reduce high-exposure product and occupational pathways, and support source control. EPA MCLs for PFOA/PFOS operationalize that population goal. Individual oncology symptoms always need medical evaluation regardless of PFAS story. Do not delay care waiting for a perfect exposure reconstruction. Sources: [IARC 2023 PFOA/PFOS evaluation](https://www.iarc.who.int/news-events/iarc-monographs-evaluate-the-carcinogenicity-of-perfluorooctanoic-acid-pfoa-and-perfluorooctanesulfonic-acid-pfos/); [C8 cancer probable link report](https://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Cancer_16April2012_v2.pdf); [ATSDR clinical evaluation PFAS](https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-management.html). Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. ## Sources 1. [IARC 2023 PFOA/PFOS evaluation](https://www.iarc.who.int/news-events/iarc-monographs-evaluate-the-carcinogenicity-of-perfluorooctanoic-acid-pfoa-and-perfluorooctanesulfonic-acid-pfos/) 2. [C8 cancer probable link report](https://www.c8sciencepanel.org/pdfs/Probable_Link_C8_Cancer_16April2012_v2.pdf) 3. [ATSDR clinical evaluation PFAS](https://www.atsdr.cdc.gov/pfas/hcp/clinical-overview/clinical-evaluation-management.html) --- Source: https://healthcanon.com/environmental-health/pfas-cancer-endpoints-evidence Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt